JPWO2020037206A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020037206A5 JPWO2020037206A5 JP2021507972A JP2021507972A JPWO2020037206A5 JP WO2020037206 A5 JPWO2020037206 A5 JP WO2020037206A5 JP 2021507972 A JP2021507972 A JP 2021507972A JP 2021507972 A JP2021507972 A JP 2021507972A JP WO2020037206 A5 JPWO2020037206 A5 JP WO2020037206A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- oncolytic virus
- virus
- disease
- oncolytic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 82
- 244000309459 oncolytic virus Species 0.000 claims description 69
- 206010028980 Neoplasm Diseases 0.000 claims description 35
- 201000011510 cancer Diseases 0.000 claims description 35
- 241000700562 Myxoma virus Species 0.000 claims description 29
- 230000014509 gene expression Effects 0.000 claims description 28
- 102000008096 B7-H1 Antigen Human genes 0.000 claims description 23
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 23
- 201000010099 disease Diseases 0.000 claims description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 23
- 102000013462 Interleukin-12 Human genes 0.000 claims description 22
- 108010065805 Interleukin-12 Proteins 0.000 claims description 22
- 229940117681 interleukin-12 Drugs 0.000 claims description 22
- 230000000174 oncolytic effect Effects 0.000 claims description 22
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 21
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 21
- 238000011319 anticancer therapy Methods 0.000 claims description 20
- 238000002560 therapeutic procedure Methods 0.000 claims description 15
- 201000001441 melanoma Diseases 0.000 claims description 14
- 241000700605 Viruses Species 0.000 claims description 12
- 230000003612 virological effect Effects 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 10
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 10
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 10
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 10
- 238000009169 immunotherapy Methods 0.000 claims description 10
- 229960002621 pembrolizumab Drugs 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims description 6
- 108700026244 Open Reading Frames Proteins 0.000 claims description 6
- 102000048362 human PDCD1 Human genes 0.000 claims description 6
- 208000009091 myxoma Diseases 0.000 claims description 6
- 206010005003 Bladder cancer Diseases 0.000 claims description 5
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 5
- 102000004127 Cytokines Human genes 0.000 claims description 5
- 108090000695 Cytokines Proteins 0.000 claims description 5
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 5
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims description 5
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims description 5
- 206010033128 Ovarian cancer Diseases 0.000 claims description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
- 206010060862 Prostate cancer Diseases 0.000 claims description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 5
- 206010038389 Renal cancer Diseases 0.000 claims description 5
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 5
- 238000011122 anti-angiogenic therapy Methods 0.000 claims description 5
- 229960003852 atezolizumab Drugs 0.000 claims description 5
- 229950002916 avelumab Drugs 0.000 claims description 5
- 238000002512 chemotherapy Methods 0.000 claims description 5
- 229950009791 durvalumab Drugs 0.000 claims description 5
- 238000001415 gene therapy Methods 0.000 claims description 5
- 201000010536 head and neck cancer Diseases 0.000 claims description 5
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 5
- 238000001794 hormone therapy Methods 0.000 claims description 5
- 229960005386 ipilimumab Drugs 0.000 claims description 5
- 201000010982 kidney cancer Diseases 0.000 claims description 5
- 208000032839 leukemia Diseases 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 239000003550 marker Substances 0.000 claims description 5
- 208000021039 metastatic melanoma Diseases 0.000 claims description 5
- 229960003301 nivolumab Drugs 0.000 claims description 5
- 238000001959 radiotherapy Methods 0.000 claims description 5
- 238000001356 surgical procedure Methods 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 5
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 5
- 102100031351 Galectin-9 Human genes 0.000 claims description 4
- 101100229077 Gallus gallus GAL9 gene Proteins 0.000 claims description 4
- 108010048367 enhanced green fluorescent protein Proteins 0.000 claims description 4
- 230000035772 mutation Effects 0.000 claims description 4
- 230000002018 overexpression Effects 0.000 claims description 4
- 241000711404 Avian avulavirus 1 Species 0.000 claims description 2
- 241000709687 Coxsackievirus Species 0.000 claims description 2
- 108060003951 Immunoglobulin Proteins 0.000 claims description 2
- 241000712079 Measles morbillivirus Species 0.000 claims description 2
- 101100284390 Mus musculus Havcr2 gene Proteins 0.000 claims description 2
- 241000709664 Picornaviridae Species 0.000 claims description 2
- 241000125945 Protoparvovirus Species 0.000 claims description 2
- 241000702263 Reovirus sp. Species 0.000 claims description 2
- 241000700584 Simplexvirus Species 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- 102000018358 immunoglobulin Human genes 0.000 claims description 2
- 102220330185 rs1364834319 Human genes 0.000 claims description 2
- 241001430294 unidentified retrovirus Species 0.000 claims description 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 6
- 102000000588 Interleukin-2 Human genes 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 229940124622 immune-modulator drug Drugs 0.000 claims 1
- 230000003362 replicative effect Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000002519 immonomodulatory effect Effects 0.000 description 4
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 2
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862718990P | 2018-08-16 | 2018-08-16 | |
| US62/718,990 | 2018-08-16 | ||
| US201862741404P | 2018-10-04 | 2018-10-04 | |
| US62/741,404 | 2018-10-04 | ||
| US201862754622P | 2018-11-02 | 2018-11-02 | |
| US62/754,622 | 2018-11-02 | ||
| US201962813375P | 2019-03-04 | 2019-03-04 | |
| US62/813,375 | 2019-03-04 | ||
| PCT/US2019/046823 WO2020037206A1 (en) | 2018-08-16 | 2019-08-16 | Recombinant myxoma viruses and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021533789A JP2021533789A (ja) | 2021-12-09 |
| JPWO2020037206A5 true JPWO2020037206A5 (https=) | 2022-08-22 |
| JP2021533789A5 JP2021533789A5 (https=) | 2022-08-22 |
Family
ID=69525939
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021507972A Pending JP2021533789A (ja) | 2018-08-16 | 2019-08-16 | 組換え粘液腫ウイルスおよびその使用法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210196771A1 (https=) |
| EP (1) | EP3837354A4 (https=) |
| JP (1) | JP2021533789A (https=) |
| KR (1) | KR20210094509A (https=) |
| CN (1) | CN112771157A (https=) |
| AU (1) | AU2019321667A1 (https=) |
| BR (1) | BR112021002639A2 (https=) |
| CA (1) | CA3109216A1 (https=) |
| IL (1) | IL280854A (https=) |
| MX (1) | MX2021001883A (https=) |
| WO (1) | WO2020037206A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3106202A1 (en) | 2018-07-13 | 2020-01-16 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods of treating cancer with tnf expressing myxoma virus |
| US11591616B1 (en) | 2019-04-22 | 2023-02-28 | Colorado State University Research Foundation | Apoptotic upregulation by myxoma virus expressing walleye dermal sarcoma virus orfC |
| AU2020315800A1 (en) | 2019-07-19 | 2022-03-03 | Seneca Therapeutics, Inc. | Second generation seneca valley virus oncolytic therapy: compositions and methods thereof |
| MX2022002547A (es) | 2019-09-02 | 2022-05-18 | Univ Arizona State | Una nueva plataforma de virus oncoliticos para tratar canceres con virus myxoma. |
| US20240091284A1 (en) * | 2019-10-10 | 2024-03-21 | Arizona Board Of Regents On Behalf Of Arizona State University | Oncolytic virus comprising immunomodulatory transgenes and uses thereof |
| AU2021224730A1 (en) * | 2020-02-20 | 2022-09-22 | Musc Foundation For Research Development | Recombinant myxoma viruses and uses thereof |
| JP2023548746A (ja) | 2020-10-13 | 2023-11-21 | クリヤ セラピューティクス インコーポレイテッド | サイトカインをコードする核酸を送達するためのウイルスベクターコンストラクトおよびがんを処置するためのその使用 |
| WO2022139440A1 (ko) * | 2020-12-22 | 2022-06-30 | 바이로큐어 주식회사 | 신규한 재조합 믹소마바이러스 및 이의 용도 |
| WO2022159508A1 (en) * | 2021-01-19 | 2022-07-28 | Seneca Therapeutics, Inc. | Armed seneca valley virus oncolytic therapy compositions and methods thereof |
| CA3210350A1 (en) * | 2021-03-01 | 2022-09-09 | Leslie Lynne Sharp | Multi-armed myxoma virus |
| CA3245584A1 (en) | 2022-03-10 | 2023-09-14 | City Of Hope | IL-12 Bound to the Membrane for Cellular Immunotherapy |
| WO2024111633A1 (ja) * | 2022-11-24 | 2024-05-30 | 国立大学法人徳島大学 | タンパク質に対する抗体の作製 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2670804A1 (en) * | 2006-05-19 | 2007-11-29 | Sanofi Pasteur Inc. | Immunological composition |
| WO2008070367A2 (en) * | 2006-11-01 | 2008-06-12 | Facet Biotech Corporation | Mammalian cell-based immunoglobulin display libraries |
| FR2946536B1 (fr) * | 2009-06-11 | 2011-07-29 | Agronomique Inst Nat Rech | Utilisation d'une souche attenuee de myxoma virus comme oncolytique |
| DK3169341T3 (da) * | 2014-07-16 | 2019-08-05 | Transgene Sa | Onkolytisk virus til ekspression af immun-checkpoint-modulatorer |
| PL3368572T3 (pl) * | 2015-10-02 | 2022-09-12 | Symphogen A/S | Przeciwciała anty-PD-1 oraz kompozycje |
| WO2017072539A1 (en) * | 2015-10-27 | 2017-05-04 | Pharmassist Ltd | Method for the quantification of pd-l1 expression |
| WO2018049261A1 (en) * | 2016-09-09 | 2018-03-15 | Icellhealth Consulting Llc | Oncolytic virus expressing immune checkpoint modulators |
-
2019
- 2019-08-16 AU AU2019321667A patent/AU2019321667A1/en not_active Abandoned
- 2019-08-16 EP EP19849867.7A patent/EP3837354A4/en not_active Withdrawn
- 2019-08-16 BR BR112021002639-8A patent/BR112021002639A2/pt not_active Application Discontinuation
- 2019-08-16 KR KR1020217006855A patent/KR20210094509A/ko not_active Ceased
- 2019-08-16 MX MX2021001883A patent/MX2021001883A/es unknown
- 2019-08-16 CA CA3109216A patent/CA3109216A1/en active Pending
- 2019-08-16 US US17/268,656 patent/US20210196771A1/en not_active Abandoned
- 2019-08-16 JP JP2021507972A patent/JP2021533789A/ja active Pending
- 2019-08-16 CN CN201980060542.9A patent/CN112771157A/zh active Pending
- 2019-08-16 WO PCT/US2019/046823 patent/WO2020037206A1/en not_active Ceased
-
2021
- 2021-02-14 IL IL280854A patent/IL280854A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021533789A5 (https=) | ||
| O'Bryan et al. | Oncolytic virotherapy for breast cancer treatment | |
| WO2020037206A4 (en) | Recombinant myxoma viruses and uses thereof | |
| JP7295192B2 (ja) | 改変された腫瘍溶解性ウイルス | |
| JP6794442B2 (ja) | 新規な遺伝子組換えワクシニアウイルス | |
| JP6420776B2 (ja) | 免疫療法のためのエンゲージャー細胞 | |
| CN110872577B (zh) | 修饰的免疫细胞及其应用 | |
| US20220056480A1 (en) | Modified orthopoxvirus vectors | |
| BR112019013215A2 (pt) | vírus oncolítico, composição farmacêutica, produto de fabricação, método para tratar câncer e uso | |
| Zaoui et al. | Chemovirotherapy for head and neck squamous cell carcinoma with EGFR-targeted and CD/UPRT-armed oncolytic measles virus | |
| Huang et al. | Bispecific T cell engagers and their synergistic tumor immunotherapy with oncolytic viruses | |
| JPWO2020037206A5 (https=) | ||
| WO2024119769A1 (zh) | 增强向肿瘤部位浸润能力的car-nk细胞制备及应用 | |
| CN110564767A (zh) | 一种减毒病毒载体系统及其在制备抗恶性肿瘤的药物中的应用及药物使用方法 | |
| BR112021001117A2 (pt) | células cancerígenas modificadas, composição farmacêutica, linha celular, métodos para fazer células cancerígenas modificadas e para estimular uma resposta imune, vetor de expressão isolado ou combinação de vetores de expressão isolados, e, uma ou mais células cancerígenas modificadas | |
| EP4041752A2 (en) | Canine distemper virus hemagglutinin and fusion polypeptides | |
| CN117264043A (zh) | 靶向kras g12v突变多肽的t细胞受体及其用途 | |
| Akunne et al. | Emerging strategies in cancer immunotherapy: Expanding horizons and future perspectives | |
| JP2023533567A (ja) | 組み換えワクシニアウイルス | |
| US20220090132A1 (en) | Car t cell methods and constructs | |
| US20250297002A1 (en) | Bispecific t-cell engager, recombinant oncolytic virus thereof, and use thereof | |
| CN117924518B (zh) | 用于nk细胞的嵌合抗原受体及工程化的nk细胞 | |
| WO2024139235A1 (zh) | 一种拮抗泛素化降解的突变型e1a及其在制备增效型溶瘤腺病毒和免疫增效剂中的应用 | |
| RU2021106556A (ru) | Рекомбинантные вирусы миксомы и их применения | |
| CN116059329A (zh) | 溶瘤病毒与car t细胞联合治疗血液肿瘤的方法 |